Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session 1 - Gastrointestinal tumours, upper digestive

945MO - AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) + tislelizumab (TIS) + BAT1706 (bevacizumab biosimilar) versus TIS + BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC)

Date

21 Oct 2023

Session

Mini oral session 1 - Gastrointestinal tumours, upper digestive

Topics

Tumour Site

Hepatobiliary Cancers

Presenters

Ming Mo Hou

Citation

Annals of Oncology (2023) 34 (suppl_2): S594-S618. 10.1016/S0923-7534(23)01939-7

Authors

Z. Ren1, Y. Huang2, Y. Guo3, M.M. Hou4, W. Wang5, M. Kuang6, C. Hao7, W. Wang8, Y. Zhang9, T. Song10, C. Dai11, K. Hsing-Tao12, V. Li13, R. Abdrashitov14, L. Wang15, J. Fan16

Author affiliations

  • 1 Department Of Hepatic Oncology, Zhongshan Hospital Fudan University, 200032 - Shanghai/CN
  • 2 Department Of Hepatic Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou/CN
  • 3 Liver Tumor Center, Nanfang Hospital, Southern Medical University, 510515 - Guangzhou/CN
  • 4 Pediatric Hematology & Oncology, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, 33305 - Taoyuan City/TW
  • 5 Gastroenterology And Urology Department, Hunan Cancer Hospital, 410013 - Changsha/CN
  • 6 Department Of Hepatic Surgery, The First Affiliated Hospital of Sun Yat-sen University, 510080 - Guangzhou/CN
  • 7 Department Of Hepato-pancreato-biliary Surgery, Beijing Cancer Hospital, 100142 - Beijing/CN
  • 8 Department Of Liver Surgery, West China Hospital Sichuan University, Sichuan/CN
  • 9 9. gastroenterology Department, Harbin Medical University Cancer Hospital, 150084 - Harbin/CN
  • 10 Department Of Hepatobiliary, HCC Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, 300011 - Tianjin/CN
  • 11 Department Of Hepatobiliary And Splenic Surgery, Shengjing Hospital of China Medical University - Huaxiang Campus, Shenyang/CN
  • 12 Gastroenterohepatobiliary Department, Chi Mei Medical Center - Chiali, 71004 - Tainan City/TW
  • 13 Clinical Development, Solid Tumors, BeiGene (Beijing) Co. Ltd, Beijing/CN
  • 14 Clinical Development, BeiGene USA, Inc., 20759 - Fulton/US
  • 15 Statistics, BeiGene (Beijing) Co. Ltd, Beijing/CN
  • 16 Department Of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan Hospital - Fudan University, 200032 - Shanghai/CN

Resources

This content is available to ESMO members and event participants.

Abstract 945MO

Background

Pts with advanced HCC have poor prognosis, with 5-year survival of 18%. Coinhibition of programmed death ligand-1 (PD-L1) and VEGF provides survival benefit in 1st line (1L) HCC. In preclinical studies of HCC and clinical studies of other tumors, coinhibition of T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) and PD-1 enhances antitumor activity of anti-PD-1. AdvanTIG-206 (NCT04948697) is investigating the efficacy/safety of adding OCI (anti-TIGIT) to TIS (anti-PD-1) + BAT1706 backbone as 1L therapy in advanced HCC pts.

Methods

Eligible adults had histologically confirmed HCC that is BCLC Stage B or C, not amenable to or progressed after loco-regional therapy, and with no prior systemic therapy. Pts were randomized 2:1 to OCI 900 mg + TIS 200 mg + BAT1706 15 mg/kg (O+T+B) or T+B every 3 weeks until loss of clinical benefit at investigator (INV) discretion. Primary endpoint was INV-assessed objective response rate (ORR). Secondary endpoints included duration of response (DOR), progression-free survival (PFS), and overall survival (OS).

Results

As of 27 Feb 2023, 94 pts (median age 58.5 years) were randomized to O+T+B (n=62) and T+B (n=32). INV-assessed ORR was 35.5% with O+T+B vs. 37.5% with T+B (Table). For O+T+B and T+B, respectively, Grade ≥3 treatment-related adverse events (TRAEs) were 50.0% and 25.8%, most common (≥5% incidence) TRAEs were hypertension (14.5% and 6.5%) and proteinuria (both 6.5%); TRAEs that led to any treatment discontinuation were 16.1% and 6.5%. Three (4.8%) treatment-related deaths occurred with O+T+B vs. none with T+B. Table: 945MO

Efficacy

Best overall responsea, n (%) O+T+B (n=62) T+B (n=32)
Complete response 0 0
Partial response 22 (35.5) 12 (37.5)
Stable disease 26 (41.9) 11 (34.4)
Progressive disease 10 (16.1) 7 (21.9)
Not evaluable 4 (6.5) 2 (6.3)
ORR a , % (95% CI) 35.5 (23.7, 48.7) 37.5 (21.1, 56.3) 2-sided P=0.8350
DOR b (months), median (95% CI) 12.6 (7.0, NE) 10.6 (4.2, NE)
PFS (months), median (95% CI) 8.3 (5.5, 10.0) 6.9 (4.1, NE) Hazard ratio = 1.08 (0.59, 1.96) 1-sided P=0.4056

Median follow-up was 9.2 months P-value is for descriptive purpose only. NE, not estimable aINV-confirmed per RECIST v1.1 bOnly includes pts with confirmed complete/partial response

Conclusions

In pts with advanced HCC, TIS + BAT1706 demonstrated promising ORR, while adding OCI to the doublet was not associated with improved anticancer activity. No new safety signals were identified in either arm. The OS data are premature and need further follow-up.

Clinical trial identification

Editorial acknowledgement

Medical writing support, under the direction of the authors, was provided by Smitha Reddy, PhD, and Nate Connors, PhD CMPP, of Envision Pharma Group, and was funded by BeiGene.

Legal entity responsible for the study

BeiGene.

Funding

BeiGene.

Disclosure

C. Dai: Financial Interests, Personal, Other, Grant: Education Department of Liaoning Province. V. Li, R. Abdrashitov, L. Wang: Financial Interests, Other, Employment: BeiGene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.